UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2023, the highest number of AIDS-related deaths occurred in South Africa and Nigeria and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was 16.2. That number has since decreased to 1.3 per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

In 2023, South Africa and Nigeria had the highest number of deaths due to AIDS worldwide, with around ** thousand and ** thousand such deaths, respectively. African countries account for eight of the top 10 countries with the highest number of AIDS-related deaths worldwide. AIDS-related deaths worldwide have been gradually declining over the past decade, decreasing from *** million deaths in 2010 to *** thousand deaths in 2023. HIV/AIDS HIV (human immunodeficiency virus) is an infectious sexually transmitted disease that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV weakens the human immune system, resulting in the affected person being unable to fight off opportunistic infections. The top 15 countries worldwide with the highest prevalence of new HIV infections as of 2023 were all African. HIV treatment Although there is currently no effective cure for HIV, death can be prevented by taking HIV antiretroviral therapy (ART). Access to antiretroviral therapy worldwide has significantly increased in the past decade. As of 2023, around **** million people with HIV worldwide were receiving ART. The leading countries with the highest percentage of HIV-infected children who were receiving ART were Eswatini, Kenya, and Lesotho.

UNAIDS estimated that there were some 630,000 people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2023. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2023. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2023, the highest number of AIDS-related deaths occurred in South Africa and Nigeria and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost 40 million in 2023. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

In 2024, there were approximately 260 thousand AIDS-related deaths in Eastern and Southern Africa. This statistic depicts the estimated number of AIDS-related deaths worldwide in 2024, sorted by region.

In 2023, there were around 13.5 deaths due to tuberculosis per 100,000 people who were HIV-negative worldwide. In comparison, the tuberculosis mortality rate among people who were HIV-positive was two per 100,000 population. This statistic shows the mortality rate of tuberculosis worldwide from 2010 to 2023, by HIV status.

BackgroundSince the first HIV/AIDS case appeared in 1980s, HIV/AIDS has been the focus of international attention. As a major public health problem, there are epidemiological uncertainties about the future of HIV/AIDS. It is important to monitor the global statistics of HIV/AIDS prevalence, deaths, disability adjusted life years (DALYs), and risk factors for adequate prevention and control.MethodsThe Global Burden of Disease Study 2019 database was used to analyze the burden of HIV/AIDS in 1990–2019. By extracting global, regional, and national data on HIV/AIDS prevalence, deaths, and DALYs, we described the distribution by age and sex, explored the risk factors, and analyzed the trends in HIV/AIDS.ResultsIn 2019, there were 36.85 million HIV/AIDS cases (95% UI: 35.15–38.86 million), 863.84 thousand deaths (95% UI: 78.61–99.60 thousand), and 47.63 million (95% UI: 42.63–55.65 million) DALYs. The global age-standardized HIV/AIDS prevalence, death, and DALY rates were 454.32 (95% UI: 433.76–478.59), 10.72 (95% UI: 9.70–12.39), and 601.49 (95% UI: 536.16–703.92) per 100,000 cases, respectively. In 2019, the global age-standardized HIV/AIDS prevalence, death, and DALY rates increased by 307.26 (95% UI: 304.45–312.63), 4.34 (95% UI: 3.78–4.90), and 221.91 (95% UI: 204.36–239.47) per 100,000 cases, respectively, compared to 1990. Age-standardized prevalence, death, and DALY rates decreased in high sociodemographic index (SDI) areas. High age-standardized rates were observed in low sociodemographic index areas, while low age-standardized rates were observed in high sociodemographic index areas. In 2019, the high age-standardized prevalence, death, and DALY rates were predominant in Southern Sub-Saharan Africa, and global DALYs peaked in 2004 and subsequently decreased. The highest global HIV/AIDS DALYs were in the 40–44 age group. The main risk factors affecting HIV/AIDS DALY rates included behavioral risks, drug use, partner violence, and unsafe sex.ConclusionsHIV/AIDS disease burden and risk factors vary by region, sex, and age. As access to health care increases across countries and treatment for HIV/AIDS infection improves, the HIV/AIDS disease burden is concentrated in areas with low SDIs, particularly in South Africa. Regional differences should be fully considered to target optimal prevention strategies and treatment options based on risk factors.

IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 7.200 NA in 2016. This records a decrease from the previous number of 7.300 NA for 2015. IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 7.500 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 9.300 NA in 2000 and a record low of 7.200 NA in 2016. IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

In 2023, around *** out of 100 thousand Canadians died from HIV. In 2000, the death rate stood at approximately *** deaths per 100,000. This statistic displays the age-standardized death rates in Canada for HIV from 2000 to 2023. HIV in Canada Human immunodeficiency virus (HIV) is a contagious virus that weakens the body’s immune system. Without treatment, over time the damage caused by the virus can progress to AIDS, where the body is unable to fight other infections, leading to death. In Canada, the number of newly reported cases of HIV has fluctuated between around ***** and ***** per year over the past twenty years, with the rate of reported cases around **** per 100,000 population in 2022. HIV worldwide Although the number of people living with HIV is rising worldwide, the number of new HIV infections has decreased by nearly half in the past twenty years. This is due to better treatment, especially antiretroviral therapy, which allows those with HIV to live longer, healthier lives. Global health organizations have established strategies to try to eliminate AIDS as a public health threat, focusing mostly on increasing awareness and early identification of cases, providing methods to avoid passing on the virus, as well as providing treatment with the goal of viral suppression. Although there is no known cure, the majority of the funding for HIV/AIDS research and development over recent years has been provided for further work on creating HIV vaccines.

No. of Deaths: Caused by: HIV Disease (Aids) data was reported at 547.000 Person in Sep 2024. This records a decrease from the previous number of 557.000 Person for Jun 2024. No. of Deaths: Caused by: HIV Disease (Aids) data is updated quarterly, averaging 558.000 Person from Mar 2017 (Median) to Sep 2024, with 30 observations. The data reached an all-time high of 659.000 Person in Mar 2018 and a record low of 461.000 Person in Sep 2020. No. of Deaths: Caused by: HIV Disease (Aids) data remains active status in CEIC and is reported by National Administrative Department of Statistics. The data is categorized under Global Database’s Colombia – Table CO.G012: Number of Deaths: Cause of Death.

BackgroundGlobal and regional projections of mortality and burden of disease by cause for the years 2000, 2010, and 2030 were published by Murray and Lopez in 1996 as part of the Global Burden of Disease project. These projections, which are based on 1990 data, continue to be widely quoted, although they are substantially outdated; in particular, they substantially underestimated the spread of HIV/AIDS. To address the widespread demand for information on likely future trends in global health, and thereby to support international health policy and priority setting, we have prepared new projections of mortality and burden of disease to 2030 starting from World Health Organization estimates of mortality and burden of disease for 2002. This paper describes the methods, assumptions, input data, and results. Methods and FindingsRelatively simple models were used to project future health trends under three scenarios—baseline, optimistic, and pessimistic—based largely on projections of economic and social development, and using the historically observed relationships of these with cause-specific mortality rates. Data inputs have been updated to take account of the greater availability of death registration data and the latest available projections for HIV/AIDS, income, human capital, tobacco smoking, body mass index, and other inputs. In all three scenarios there is a dramatic shift in the distribution of deaths from younger to older ages and from communicable, maternal, perinatal, and nutritional causes to noncommunicable disease causes. The risk of death for children younger than 5 y is projected to fall by nearly 50% in the baseline scenario between 2002 and 2030. The proportion of deaths due to noncommunicable disease is projected to rise from 59% in 2002 to 69% in 2030. Global HIV/AIDS deaths are projected to rise from 2.8 million in 2002 to 6.5 million in 2030 under the baseline scenario, which assumes coverage with antiretroviral drugs reaches 80% by 2012. Under the optimistic scenario, which also assumes increased prevention activity, HIV/AIDS deaths are projected to drop to 3.7 million in 2030. Total tobacco-attributable deaths are projected to rise from 5.4 million in 2005 to 6.4 million in 2015 and 8.3 million in 2030 under our baseline scenario. Tobacco is projected to kill 50% more people in 2015 than HIV/AIDS, and to be responsible for 10% of all deaths globally. The three leading causes of burden of disease in 2030 are projected to include HIV/AIDS, unipolar depressive disorders, and ischaemic heart disease in the baseline and pessimistic scenarios. Road traffic accidents are the fourth leading cause in the baseline scenario, and the third leading cause ahead of ischaemic heart disease in the optimistic scenario. Under the baseline scenario, HIV/AIDS becomes the leading cause of burden of disease in middle- and low-income countries by 2015. ConclusionsThese projections represent a set of three visions of the future for population health, based on certain explicit assumptions. Despite the wide uncertainty ranges around future projections, they enable us to appreciate better the implications for health and health policy of currently observed trends, and the likely impact of fairly certain future trends, such as the ageing of the population, the continued spread of HIV/AIDS in many regions, and the continuation of the epidemiological transition in developing countries. The results depend strongly on the assumption that future mortality trends in poor countries will have a relationship to economic and social development similar to those that have occurred in the higher-income countries.

Tuberculosis is one of the deadliest communicable diseases worldwide, causing around *** million deaths per year. Communicable diseases, also known as infectious diseases, are spread from person to person either directly or indirectly, such as through an insect bite or ingesting contaminated food or water. Some of the deadliest communicable diseases include HIV/AIDS, malaria, hepatitis C, cholera, and measles. Tuberculosis Tuberculosis is an infectious disease that affects the lungs. Tuberculosis disproportionately impacts the poorer, less developed countries of the world, such as in Africa and Southeast Asia. India reports the highest number of deaths from tuberculosis worldwide. HIV/AIDS Although deaths from HIV/AIDS have decreased over the last few decades, there were still around ******* AIDS-related deaths in 2023. Like many other communicable diseases, HIV/AIDS impacts developing regions more than the developed world. By far, the highest number of AIDS deaths come from Africa and Asia Pacific. Advancements in HIV treatment now allow those infected to live long and relatively normal lives, but access to treatment varies greatly.

Users can access data related to international women’s health as well as data on population and families, education, work, power and decision making, violence against women, poverty, and environment. Background World’s Women Reports are prepared by the Statistics Division of the United Nations Department for Economic and Social Affairs (UNDESA). Reports are produced in five year intervals and began in 1990. A major theme of the reports is comparing women’s situation globally to that of men in a variety of fields. Health data is available related to life expectancy, cause of death, chronic disease, HIV/AIDS, prenatal care, maternal morbidity, reproductive health, contraceptive use, induced abortion, mortality of children under 5, and immunization. User functionality Users can download full text or specific chapter versions of the reports in color and black and white. A limited number of graphs are available for download directly from the website. Topics include obesity and underweight children. Data Notes The report and data tables are available for download in PDF format. The next report is scheduled to be released in 2015. The most recent report was released in 2010.

Liberia LR: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 17.500 NA in 2016. This records an increase from the previous number of 16.900 NA for 2015. Liberia LR: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 17.900 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 18.900 NA in 2005 and a record low of 16.900 NA in 2015. Liberia LR: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Liberia – Table LR.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Goal 3Ensure healthy lives and promote well-being for all at all agesTarget 3.1: By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live birthsIndicator 3.1.1: Maternal mortality ratioSH_STA_MORT: Maternal mortality ratioIndicator 3.1.2: Proportion of births attended by skilled health personnelSH_STA_BRTC: Proportion of births attended by skilled health personnel (%)Target 3.2: By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live birthsIndicator 3.2.1: Under-5 mortality rateSH_DYN_IMRTN: Infant deaths (number)SH_DYN_MORT: Under-five mortality rate, by sex (deaths per 1,000 live births)SH_DYN_IMRT: Infant mortality rate (deaths per 1,000 live births)SH_DYN_MORTN: Under-five deaths (number)Indicator 3.2.2: Neonatal mortality rateSH_DYN_NMRTN: Neonatal deaths (number)SH_DYN_NMRT: Neonatal mortality rate (deaths per 1,000 live births)Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseasesIndicator 3.3.1: Number of new HIV infections per 1,000 uninfected population, by sex, age and key populationsSH_HIV_INCD: Number of new HIV infections per 1,000 uninfected population, by sex and age (per 1,000 uninfected population)Indicator 3.3.2: Tuberculosis incidence per 100,000 populationSH_TBS_INCD: Tuberculosis incidence (per 100,000 population)Indicator 3.3.3: Malaria incidence per 1,000 populationSH_STA_MALR: Malaria incidence per 1,000 population at risk (per 1,000 population)Indicator 3.3.4: Hepatitis B incidence per 100,000 populationSH_HAP_HBSAG: Prevalence of hepatitis B surface antigen (HBsAg) (%)Indicator 3.3.5: Number of people requiring interventions against neglected tropical diseasesSH_TRP_INTVN: Number of people requiring interventions against neglected tropical diseases (number)Target 3.4: By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-beingIndicator 3.4.1: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory diseaseSH_DTH_NCOM: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease (probability)SH_DTH_NCD: Number of deaths attributed to non-communicable diseases, by type of disease and sex (number)Indicator 3.4.2: Suicide mortality rateSH_STA_SCIDE: Suicide mortality rate, by sex (deaths per 100,000 population)SH_STA_SCIDEN: Number of deaths attributed to suicide, by sex (number)Target 3.5: Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcoholIndicator 3.5.1: Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disordersSH_SUD_ALCOL: Alcohol use disorders, 12-month prevalence (%)SH_SUD_TREAT: Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders (%)Indicator 3.5.2: Alcohol per capita consumption (aged 15 years and older) within a calendar year in litres of pure alcoholSH_ALC_CONSPT: Alcohol consumption per capita (aged 15 years and older) within a calendar year (litres of pure alcohol)Target 3.6: By 2020, halve the number of global deaths and injuries from road traffic accidentsIndicator 3.6.1: Death rate due to road traffic injuriesSH_STA_TRAF: Death rate due to road traffic injuries, by sex (per 100,000 population)Target 3.7: By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmesIndicator 3.7.1: Proportion of women of reproductive age (aged 15–49 years) who have their need for family planning satisfied with modern methodsSH_FPL_MTMM: Proportion of women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (% of women aged 15-49 years)Indicator 3.7.2: Adolescent birth rate (aged 10–14 years; aged 15–19 years) per 1,000 women in that age groupSP_DYN_ADKL: Adolescent birth rate (per 1,000 women aged 15-19 years)Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for allIndicator 3.8.1: Coverage of essential health servicesSH_ACS_UNHC: Universal health coverage (UHC) service coverage indexIndicator 3.8.2: Proportion of population with large household expenditures on health as a share of total household expenditure or incomeSH_XPD_EARN25: Proportion of population with large household expenditures on health (greater than 25%) as a share of total household expenditure or income (%)SH_XPD_EARN10: Proportion of population with large household expenditures on health (greater than 10%) as a share of total household expenditure or income (%)Target 3.9: By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contaminationIndicator 3.9.1: Mortality rate attributed to household and ambient air pollutionSH_HAP_ASMORT: Age-standardized mortality rate attributed to household air pollution (deaths per 100,000 population)SH_STA_AIRP: Crude death rate attributed to household and ambient air pollution (deaths per 100,000 population)SH_STA_ASAIRP: Age-standardized mortality rate attributed to household and ambient air pollution (deaths per 100,000 population)SH_AAP_MORT: Crude death rate attributed to ambient air pollution (deaths per 100,000 population)SH_AAP_ASMORT: Age-standardized mortality rate attributed to ambient air pollution (deaths per 100,000 population)SH_HAP_MORT: Crude death rate attributed to household air pollution (deaths per 100,000 population)Indicator 3.9.2: Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (exposure to unsafe Water, Sanitation and Hygiene for All (WASH) services)SH_STA_WASH: Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (deaths per 100,000 population)Indicator 3.9.3: Mortality rate attributed to unintentional poisoningSH_STA_POISN: Mortality rate attributed to unintentional poisonings, by sex (deaths per 100,000 population)Target 3.a: Strengthen the implementation of the World Health Organization Framework Convention on Tobacco Control in all countries, as appropriateIndicator 3.a.1: Age-standardized prevalence of current tobacco use among persons aged 15 years and olderSH_PRV_SMOK: Age-standardized prevalence of current tobacco use among persons aged 15 years and older, by sex (%)Target 3.b: Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for allIndicator 3.b.1: Proportion of the target population covered by all vaccines included in their national programmeSH_ACS_DTP3: Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)SH_ACS_MCV2: Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) (%)SH_ACS_PCV3: Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)SH_ACS_HPV: Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) (%)Indicator 3.b.2: Total net official development assistance to medical research and basic health sectorsDC_TOF_HLTHNT: Total official development assistance to medical research and basic heath sectors, net disbursement, by recipient countries (millions of constant 2018 United States dollars)DC_TOF_HLTHL: Total official development assistance to medical research and basic heath sectors, gross disbursement, by recipient countries (millions of constant 2018 United States dollars)Indicator 3.b.3: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basisSH_HLF_EMED: Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis (%)Target 3.c: Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing StatesIndicator 3.c.1: Health worker density and distributionSH_MED_DEN: Health worker density, by type of occupation (per 10,000 population)SH_MED_HWRKDIS: Health worker distribution, by sex and type of occupation (%)Target 3.d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risksIndicator 3.d.1: International Health Regulations (IHR) capacity and health emergency preparednessSH_IHR_CAPS: International Health Regulations (IHR) capacity, by type of IHR capacity (%)Indicator 3.d.2: Percentage of bloodstream infections due to selected antimicrobial-resistant organismsiSH_BLD_MRSA: Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose

Background Detailed assessments of mortality patterns, particularly age-specific mortality, represent a crucial input that enables health systems to target interventions to specific populations. Understanding how all-cause mortality has changed with respect to development status can identify exemplars for best practice. To accomplish this, the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) estimated age-specific and sex-specific all-cause mortality between 1970 and 2016 for 195 countries and territories and at the subnational level for the five countries with a population greater than 200 million in 2016. Methods We have evaluated how well civil registration systems captured deaths using a set of demographic methods called death distribution methods for adults and from consideration of survey and census data for children younger than 5 years. We generated an overall assessment of completeness of registration of deaths by dividing registered deaths in each location-year by our estimate of all-age deaths generated from our overall estimation process. For 163 locations, including subnational units in countries with a population greater than 200 million with complete vital registration (VR) systems, our estimates were largely driven by the observed data, with corrections for small fluctuations in numbers and estimation for recent years where there were lags in data reporting (lags were variable by location, generally between 1 year and 6 years). For other locations, we took advantage of different data sources available to measure under-5 mortality rates (U5MR) using complete birth histories, summary birth histories, and incomplete VR with adjustments; we measured adult mortality rate (the probability of death in individuals aged 15-60 years) using adjusted incomplete VR, sibling histories, and household death recall. We used the U5MR and adult mortality rate, together with crude death rate due to HIV in the GBD model life table system, to estimate age-specific and sex-specific death rates for each location-year. Using various international databases, we identified fatal discontinuities, which we defined as increases in the death rate of more than one death per million, resulting from conflict and terrorism, natural disasters, major transport or technological accidents, and a subset of epidemic infectious diseases; these were added to estimates in the relevant years. In 47 countries with an identified peak adult prevalence for HIV/AIDS of more than 0.5% and where VR systems were less than 65% complete, we informed our estimates of age-sex-specific mortality using the Estimation and Projection Package (EPP)-Spectrum model fitted to national HIV/AIDS prevalence surveys and antenatal clinic serosurveillance systems. We estimated stillbirths, early neonatal, late neonatal, and childhood mortality using both survey and VR data in spatiotemporal Gaussian process regression models. We estimated abridged life tables for all location-years using age-specific death rates. We grouped locations into development quintiles based on the Sociodemographic Index (SDI) and analysed mortality trends by quintile. Using spline regression, we estimated the expected mortality rate for each age-sex group as a function of SDI. We identified countries with higher life expectancy than expected by comparing observed life expectancy to anticipated life expectancy on the basis of development status alone. Findings Completeness in the registration of deaths increased from 28% in 1970 to a peak of 45% in 2013; completeness was lower after 2013 because of lags in reporting. Total deaths in children younger than 5 years decreased from 1970 to 2016, and slower decreases occurred at ages 5-24 years. By contrast, numbers of adult deaths increased in each 5-year age bracket above the age of 25 years. The distribution of annualised rates of change in age-specific mortality rate differed over the period 2000 to 2016 compared with earlier decades: increasing annualised rates of change were less frequent, although rising annualised rates of change still occurred in some locations, particularly for adolescent and younger adult age groups. Rates of stillbirths and under-5 mortality both decreased globally from 1970. Evidence for global convergence of death rates was mixed; although the absolute difference between age-standardised death rates narrowed between countries at the lowest and highest levels of SDI, the ratio of these death rates-a measure of relative inequality-increased slightly. There was a strong shift between 1970 and 2016 toward higher life expectancy, most noticeably at higher levels of SDI. Among countries with populations greater than 1 million in 2016, life expectancy at birth was highest for women in Japan, at 86.9 years (95% UI 86.7-87.2), and for men in Singapore, at 81.3 years (78.8-83.7) in 2016. Male life expectancy was generally lower than female life expectancy between 1970 and 2016, and the gap be...

In January 2025, President Trump ordered a pause on funding for the U.S. Agency for International Development (USAID) and a 90-day review of all U.S. foreign assistance. By the end of March, the review had been completed, 83 percent of USAID programs were terminated, and it was announced that certain USAID functions would be overtaken by the Department of State while all others would be discontinued. A preprint research paper posted in April 2025 looked at the possible effects that reductions or cessation of U.S. foreign aid would have on global health. The researchers estimated that the elimination of U.S. foreign aid for global health would result in an additional 15.2 million AIDS-related deaths from 2025 to 2040. Furthermore, they estimated that the loss of U.S. aid would lead to 26.2 million additional HIV infections over this period. This paper has not been peer-reviewed so the estimates should be interpreted with caution, but there is no doubt that such cuts to U.S. foreign aid will result in an increase in HIV infections and deaths, especially in high-impact countries. Trump has said that the United States spends too much on foreign aid and accused USAID of being corrupt and a waste of money. However, foreign aid accounts for just one percent of the federal budget. Furthermore, it is predicted that millions of people will die due to the dissolution of USAID, as vulnerable people around the world will no longer be able to access prevention and treatment for diseases such as HIV/AIDS, tuberculosis, and malaria.

Iraq IQ: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 24.600 NA in 2016. This records a decrease from the previous number of 24.900 NA for 2015. Iraq IQ: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 25.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 27.500 NA in 2000 and a record low of 24.600 NA in 2016. Iraq IQ: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Iraq – Table IQ.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Chad TD: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 23.400 % in 2021. This records a decrease from the previous number of 24.500 % for 2020. Chad TD: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 25.250 % from Dec 2000 (Median) to 2021, with 22 observations. The data reached an all-time high of 25.800 % in 2003 and a record low of 23.400 % in 2021. Chad TD: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Chad – Table TD.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].